Hans-Ulrich Demuth

from Wikipedia, the free encyclopedia

Hans-Ulrich Demuth (born February 27, 1953 in Halle (Saale) ) is co-founder of Probiodrug AG, honorary professor for pharmaceutical biotechnology at Anhalt University and member of the German Ethics Council .

Life

From 1973 to 1978 Hans-Ulrich Demuth studied biochemistry with a diploma at the Martin Luther University Halle-Wittenberg and received his doctorate there in 1981.

In 1997 he was a co-founder of ProBioTec GmbH for the development of anti-diabetic drugs from the then new class of active ingredients, the DPP4 inhibitors . In 2001 he became co-founder and CEO of Probiodrug AG. He has been the company's scientific advisor since 2013.

Since 2006 he has been an honorary professor for pharmaceutical biotechnology at the Anhalt University of Applied Sciences.

In 2015 he became head of the molecular drug biochemistry and therapy development (MWT) branch of the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Halle. Among other things, he is involved in research into Alzheimer's disease . He is the author of over 300 scientific articles and holds over 120 patents.

In April 2020 he was elected by the Bundestag as a member of the German Ethics Council on the proposal of the Die Linke parliamentary group .

Web links

Individual evidence

  1. Portrait of Hans-Ulrich Demuth on halle-doelau.de, accessed on May 9, 2020
  2. ^ CV Hans-Ulrich Demuth. Perinatal Center Halle, 2017, accessed on April 27, 2020 .
  3. Chairman of the board of the company "probiodrug" appointed honorary professor. Anhalt University of Applied Sciences, 2006, accessed on April 27, 2020 .
  4. Anja Garms: Researchers are looking for new therapies against forgetting. Der Tagesspiegel, September 5, 2019, accessed on April 27, 2020 .
  5. ^ Hans-Ulrich Demuth: Profile Hans-Ulrich Demuth on ResearchGate. Retrieved April 27, 2020 .
  6. ^ Jan Eisel: German Bundestag - members of the German Ethics Council elected. Retrieved April 27, 2020 .